© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 11, 861-863,
June 7, 2000
© 2000 Oxford University Press
EDITORIALS |
Gatekeeper for Endometrium: the PTEN Tumor Suppressor Gene
Affiliation of author: Division of Cancer Prevention, National Cancer Institute, Bethesda, MD.
Correspondence to: Iqbal Unnisa Ali, Ph.D., National Institutes of Health, EPN, Rm. 201, Bethesda, MD 20892-7332 (e-mail: ia1t@nih.gov).
The complexity of genetic alterations in invasive cancers and the heterogeneity of tumor cell populations hamper attempts to translate molecular understanding at the genetic level into accurate diagnostic and therapeutic approaches. Delineation of molecular changes in the initial stages of tumor development is, therefore, highly desirable because such information can be translated into more effective cancer prevention and treatment strategies. Significant advances have been made in understanding the molecular events that occur as normal tissues evolve—often into precancerous lesions, some of which eventually progress to cancer. In some cancers, such as colorectal carcinomas and gliomas, details of distinct molecular pathways have been identified. In most cancers, however, no consistent pattern of genetic alteration is convincingly linked to the initiation or progression of the disease.
In the case of endometrial cancer, molecular details are beginning to emerge that may eventually help advance our understanding of the complex histopathology of this disease.
REFERENCES
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. M Haughian, T. A Jackson, D. M Koterwas, and A. P Bradford Endometrial cancer cell survival and apoptosis is regulated by protein kinase C {alpha} and {delta} Endocr. Relat. Cancer, December 1, 2006; 13(4): 1251 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Cook, B. J. Davis, S.-L. Cai, J. C. Barrett, C. J. Conti, and C. L. Walker Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance PNAS, June 14, 2005; 102(24): 8644 - 8649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Czauderna, M. Fechtner, H. Aygun, W. Arnold, A. Klippel, K. Giese, and J. Kaufmann Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA Nucleic Acids Res., January 15, 2003; 31(2): 670 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Li, G. W. Robinson, R. Lesche, H. Martinez-Diaz, Z. Jiang, N. Rozengurt, K.-U. Wagner, D.-C. Wu, T. F. Lane, X. Liu, et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland Development, September 1, 2002; 129(17): 4159 - 4170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Levine, T. Forest, and C. Smith Tumor Suppressor PTEN is Mutated in Canine Osteosarcoma Cell Lines and Tumors Vet. Pathol., May 1, 2002; 39(3): 372 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G L Mutter Diagnosis of premalignant endometrial disease J. Clin. Pathol., May 1, 2002; 55(5): 326 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Hale, C. L. Hughes, and J. M. Cline Endometrial Cancer: Hormonal Factors, the Perimenopausal ""Window of Risk,"" and Isoflavones J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 3 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Mutter, T. A. Ince, J. P. A. Baak, G. A. Kust, X.-P. Zhou, and C. Eng Molecular Identification of Latent Precancers in Histologically Normal Endometrium Cancer Res., June 1, 2001; 61(11): 4311 - 4314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Mutter PTEN, a Protean Tumor Suppressor Am. J. Pathol., June 1, 2001; 158(6): 1895 - 1898. [Full Text] [PDF]
|
|